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Abstract: Toxins from marine animals provide molecular tools for the study of many ion channels,
including mammalian voltage-gated potassium channels of the Kv1 family. Selectivity profiling
and molecular investigation of these toxins have contributed to the development of novel drug
leads with therapeutic potential for the treatment of ion channel-related diseases or channelopathies.
Here, we review specific peptide and small-molecule marine toxins modulating Kv1 channels and
thus cover recent findings of bioactives found in the venoms of marine Gastropod (cone snails),
Cnidarian (sea anemones), and small compounds from cyanobacteria. Furthermore, we discuss
pivotal advancements at exploiting the interaction of κM-conotoxin RIIIJ and heteromeric Kv1.1/1.2
channels as prevalent neuronal Kv complex. RIIIJ’s exquisite Kv1 subtype selectivity underpins a
novel and facile functional classification of large-diameter dorsal root ganglion neurons. The vast
potential of marine toxins warrants further collaborative efforts and high-throughput approaches
aimed at the discovery and profiling of Kv1-targeted bioactives, which will greatly accelerate the
development of a thorough molecular toolbox and much-needed therapeutics.
Keywords: bioactives; conotoxins 2; Kv1; marine toxins; modulators; potassium channels; sea
anemone toxins
1. Introduction
1.1. Kv1 Channels
Voltage-gated K+ channels (Kv) are intrinsic plasma membrane proteins mediating the selective
flow of K+ ions down their electrochemical gradient in response to a depolarization in the
transmembrane electric field [1]. The selectivity and voltage dependence of Kv channels make
them central players in virtually all physiological functions, including the maintenance and modulation
of neuronal [2–4] and muscular (both cardiac and skeletal) excitability [5–7], regulation of calcium
signalling cascades (reviewed by Reference [8]), control of cell volume [9,10], immune response [11],
hormonal secretion [12], and others.
The Kv channel α-subunit belongs to the six transmembrane (6-TM) family of ion channels
(Figure 1a,b) in which the voltage-sensing domain (VSD) formed by transmembrane segments S1–S4
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controls pore opening via the S4–S5 intracellular loop that is connected to the pore domain (PD).
The PD is formed by transmembrane segments S5–S6 including a re-entrant pore loop bearing the
potassium selectivity sequence TVGYG [13]. Depolarization of the transmembrane electric field
induces a conformational change in the VSD that leads to channel activation, leading to opening of the
water-filled permeation pathway permitting K+ to flow down their electrochemical gradient. Upon
repolarization, the VSD returns to its resting state, closing the channel gate and terminating ionic
flow in a process called deactivation. Immediately after deactivation, channels can be reactivated;
however, if depolarization-induced channel activation extends beyond a few milliseconds, inactivation
ensues, ceasing K+ permeability. Kv channels recover from inactivation only after spending enough
time at a hyperpolarized potential [14]. The molecular underpinnings of the inactivation processes
have been thoroughly examined functionally and structurally, identifying various inactivation types
involving distinct and complex molecular mechanisms. Voltage-gated ion channels can inactivate from
pre-open closed-states (closed-state inactivation, CSI) or from the open state(s) (open-state inactivation,
OSI) [15]. Inactivation can also be categorized depending on the speed of its onset upon activation.
In some Kv channels, fast inactivation or N-type inactivation occurs soon after the channel activates
and it is mainly due to an intracellular block by the channel’s intracellular N-terminus hence known as
the inactivation particle [16]. This process has been directly observed by cryo-electron microscopy
(cryo-EM) in a related prokaryotic K channel [17]. In addition to N-type inactivation, a common but
relatively slower process happens after tens or hundreds of milliseconds from channel activation
that is termed C-type (or slow) inactivation [18]. Even though the extent and complexity of slow
inactivation remain the subjects of investigation, the pore structure and the permeating ions appear to
play a vital role [19]. Recent structural and functional studies support a mechanism through which the
redistribution of structural water molecules accompanies the rearrangement of amino acids within
the channel’s inner cavity and outer vestibule, ultimately leading to the collapse of the permeation
pathway in C-type inactivation (reviewed in Reference [20]). Modulation of the inactivation process is
a powerful strategy to control the cellular availability of Kv channel-mediated currents; thus, both N-
and C-type inactivation are responsive to the cellular redox environment [21]. For instance, structural
motifs within the Kv channel’s N-terminus/inactivation particle serve as sensors of the cytoplasmic
redox potential [22].
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K+ channels are the most diverse family of ion channels in excitable and nonexcitable tissues,
encompassing 40 Kv members allocated into 12 subfamilies: voltage-gated Kv subfamilies, the
Ether-à-go go (EAG) subfamily, and the Ca2+-activated subfamilies [1]. As such, they are implicated in
many neurological, cardiac, and autoimmune disorders, which position them as important therapeutic
targets [25]. The identified genes for Kv channel α-subunits are classified into twelve subfamilies:
Kv1 (Shaker); Kv2 (Shab); Kv3 (Shaw); Kv4 (Shal); Kv7 (KvLQT); Kv10 (HERG); Kv11 (EAG);
Kv12 (ELK); and the modulatory “electrically silent” Kv5, Kv6, Kv8, and Kv9 subfamilies (https:
//doi.org/10.2218/gtopdb/F81/2019.4). The Shaker-related Kv1 family is comprised of eight members
(Kv1.1–Kv1.8) encoded by the corresponding KCNA1–KCNA8 genes. Several Kv1 channels have been
identified and functionally characterized within their native tissues, exploiting selective blockers
(reviewed by References [2,26,27]). The first Kv1 complexes were purified from mammalian brain using
the snake venom toxins called dendrotoxins (DTX). These studies indicated that the functional Kv1
channel is a large (Mr ~400 kDa) sialoglycoprotein complex consisting of four pore-forming α-subunits
and four cytoplasmically associated auxiliary β-proteins [28] that modulate K+ channel activation and
inactivation kinetics (for a thorough review, refer to Reference [29]).
The Kv1 channels are expressed in a variety of tissues as homo- or heterotetrameric complexes
(Figure 1a,b) [30]. These complexes are formed in the endoplasmic reticulum [31], where monomers
are randomly recruited, assembled, and inserted in the plasma membrane [31]. The four cytoplasmic
N-terminal domains interact with one another in a strictly subfamily-specific manner, thus providing the
molecular basis for the selective formation of heteromultimeric channels in vivo [32,33]. The predominant
pathway in tetramer formation involves dimerization of subunit dimers, thereby creating interaction
sites different from those involved in the monomer–monomer association during the oligomerization
process [34].
In heterologous expression systems, all Potassium Voltage-gated channel subfamily A Member
gene (KCNA) transcripts encoding Kv1 α-subunits yield functional homo-tetrameric complexes with
distinct biophysical and pharmacological profiles [35], (Figure 1c). While theoretically, the combination
of different Kv1 subunits could afford impressive functional diversity, only a subset of oligomeric
combinations has been elucidated [36–40], suggesting their synthesis and/or assembly are carefully
orchestrated. Amongst the KV1 channels, Kv1.2 is the most prevalent isoform in neuronal membranes
where only a small fraction occurs as a homo-tetramer, while the majority are a hetero-tetramer with
other Kv1 α-subunits [36,40]. In these preparations, the less abundant Kv1.1 subunit is consistently
identified in oligomers containing Kv1.2 channels.
1.2. Mechanisms of Kv Channel Inhibition by Marine Toxins
The diversity of Kv1 channels and their wide distribution, including their specific expression
pattern in the central and peripheral nervous systems (CNS and PNS, respectively), together with their
vital function in the excitability of nerve and muscle, make them strategic targets of marine toxins.
These natural products are synthesized by marine organisms to deter competitors and to aid predation
or for self-defense [41]. Many venomous organisms block Kv channel-mediated currents, crippling
membrane repolarization, yielding enhanced excitability, and ultimately engendering paralysis in pray
or foe [42].
Marine toxins exploit different Kv channel traits to exert their modulatory actions. A commonly
used strategy relies on direct occlusion of the narrow potassium permeation pathway from the
extracellular side of the channel protein (Figure 2a,b). Toxins inhibiting ionic current via this mechanism
are referred to as “pore blockers”. Many structurally and phylogenetically unrelated pore-blocking
toxins of Kv channels share a dyad motif composed of a lysine (positive) and a tyrosine/phenylalanine
(hydrophobic) [43–45]. The lysine residue fits snugly in the Kv channel selectivity filter, sterically
occluding K+ ion flow, whilst the hydrophobic amino acid in the dyad aids docking and consolidation
of the toxin binding. This dyad motif has been proposed to be the minimal core domain of the Kv
channel-binding pharmacophore (Figure 2b) [46–49].
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Mutational analysis and docking calculations have demonstrated that some marine toxins do not
possess the canonical functional dyad or do not seem to use one in the classic “pore blocker” fashion to
prevent potassium permeation. In these toxins, a positively charged ring of amino acids participates in
electrostatic interactions with the Kv1 outer vestibule. These residues provide surface recognition and
anchoring, and concurrently, a network of hydrogen bonds and hydrophobic interactions consolidate
“capping” of the channel vestibule, with the peptide toxin acting as a lid over the Kv channel pore
(Figure 2b) [50].
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A distinct mechanism from pore block is achieved by interacting with the gating mechanism
of Kv channels. Toxins acting in this fashion are known as “gating modifiers”. The VSD in Kv
channels controls pore opening; hence, toxins binding to the extracellularly exposed linker between
transmembrane segments S3 and S4, the S3–S4 linker paddle motif within the VSD, inhibit channel
function by increasing the energy required to open the channel’s gate by shifting the voltage dependence
of activation to more depolarized potentials. Alternatively, some toxins destabilize the Kv channel
open state reflected as enhanced entry into a nonconductive inactivated state at potentials where Kv
activity would normally be favored [58]. This modulatory mechanism was first shown for Hanatoxin,
a gating modifier peptide component of the Chilean rose-hair tarantula venom that inhibits Kv2.1
channels (Figure 2a) [59].
A recently proposed inhibitory mechanism appears as a hybrid strategy between pore blockade
and gating modification. A toxin sitting in the channel’s outer vestibule blocks the extracellular
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side of the permeation pathway and modifies the permeation of water molecules into proteinaceous
peripheral cavities in the channel. This creates asymmetries in the distribution of water molecules
around the selectivity filter, triggering a local collapse of the channel pore akin to Kv C-type inactivation
(Figure 2b) [60].
2. Molluscan Peptides that Inhibit Kv1 Channels
Conotoxins constitute a family of small peptide toxins found in the venom glands of cone snails [61].
These marine gastropods of the genus Conus are represented by ~800 predatory mollusks [62]. It is
believed that the large arsenal of conotoxins within a single venom is used for fast pray immobilization
in hunting cone snails [63].
Conotoxins are typically 8–60 amino acid peptides that potently interact with a wide range of
voltage- and ligand-gated ion channels and receptors [64]. The cone snail venom peptides evolved
to capture their prey (worms, fish, and other mollusks), and their venom is known to interact and
modulate several mammalian ion channels with great selectivity [65]. The pharmacological properties
of conotoxins have been exploited as molecular tools for the study of mammalian targets [66], and
their scaffolds are employed for drug development and potential treatment of human diseases [67].
Mature conotoxins are structurally diverse, including disulfide-free and mono- and poly-disulfide-
bonded peptides (several reviews deal with the structural diversity of conotoxins; see References [64,68]).
Peptides lacking disulfide bonds are flexible, whereas the presence of multiple disulfide linkages
provides structural rigidity and provides different three-dimensional conformations depending
on the cysteine disulfide framework within the toxin sequence [69]. Cone snail VDPs are
often post-translationally modified, including C-terminal amidation, bromination, γ-carboxylation,
hydroxylation, O-glycosylation, N-terminal pyroglutamylation, and sulfation [70].
Pharmacological classification of the structurally diverse (i.e., cysteine framework/connectivity,
loop length, and fold) conotoxins is based on the target type and mechanism of action of the peptides.
Twelve pharmacological families are currently recognized (ConoServer [71]). Due to the variable
nature of conotoxins, a consensus classification-linking pharmacology to structure has not been agreed
upon. Given the nature of this review, we will focus on the pharmacological family classification of the
kappa- or κ-conotoxins, which are defined by modulatory activity over potassium-selective channels.
The founding member of the κ-conotoxins was identified in the venom of the piscivorous snail Conus
purpurascens κ-PVIIA by its potent block of Drosophila voltage-gated Shaker channels [72].
Up to now, nine conotoxins are listed as mammalian Kv1 channel blockers in the Kalium
database [73]. From those, the activity of Contryphan-Vn from Conus ventricosus against Kv1.1 and
Kv1.2 was tested by displacement of radiolabeled Bunodosoma granulifera Kv1 blocker (BgK), showing
weak activity at 600 µM [74]. Therefore, Contryphan-Vn modulatory activity against Kv1 channels
remains to be verified.
The other κ-conotoxins listed belong to various structural families of disulfide-rich peptides (A, I,
J, M, O, and the Conkunitzins; Figure 3 and Table 1). Disulfide-rich κ-conotoxins have been shown
to act as pore blockers using canonical interactions through the “functional dyad” and the “ring of
basic residues” as molecular determinants of κ-conotoxin modulation of Kv1 channel conductance.
Such mechanisms of action have been described in scorpion and cnidarian VDP toxins blocking Kv1
channels; hence, κ-conotoxins share important features that enable Kv1 channel inhibition in a similar
way to other animal VDP blockers.
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Figure 3. Structures of representative cone snail venom-derived peptide toxins κ-PVIIA (PDB:
1AV3, [75]), κM-RIIIK [51], pl14a (PDB: 2FQC, [76]), I-RXIA (PDB: 2JTU, http://www.rcsb.org/structure/
2JTU), and Conkunitzin-S1 (PDB: 2CA7, [52]): β-sheets are in cyan, and α-helices are in red.2.1.
κM-RIIIK.
Despite the great abundance of Conus peptides characterized to date, relatively few have been
shown to interact with Kv channels. κM-RIIIK from Conus radiatus [77] (Figures 2 and 3) is 24 residues
long, and it is structurally homologous to the well-known voltage-gated sodium channel blocker
µ-GIIIA [78]. RIIIK was originally identified as a Shaker (Drosophila) and TSha1 (trout) Kv1 orthologue
channel blocker [79]. Later, RIIIK became the first conotoxin described to modulate human Kv1
channels, selectively blocking homomeric Kv1.2 without apparent effects over Navs or mammalian
homologs Kv1.1, Kv1.3, Kv1.4, Kv1.5, and Kv1.6 recorded by Two Electrode Voltage Clamp recording
(TEVC) in Xenopus oocytes [77]. Interestingly, heteromerization with Kv1.2α-subunits suffices to render
Kv1.1, Kv1.5, and Kv1.7, containing heterodimeric channels sensitive to low micromolar RIIIK [80].
Binding of κM-RIIIK to closed (deactivated) Kv1.2 channels is ~2-fold stronger than to the open
state, hinting towards state-dependent interactions between this peptide and the Kv1s. Importantly,
RIIIK blocks its Kv1 channel targets, through a pharmacophore comprised of a ring of positive charges
and not via the classical “dyad motif” [51,81].
2.1. κM-RIIIJ
Further analyses of the venom of Conus radiatus revealed a second, closely related peptide, named
κM-RIIIJ, that displayed 10-fold higher potency (~30 nM) blocking homomeric Kv1.2-mediated currents.
Comparison of RIIIK and RIIIJ activity in an animal model of ischemia/reperfusion revealed that the
latter was cardioprotective, an effect adjudicated to RIIIJ’s higher potency at inhibiting heterodimeric
Kv1-mediated currents [80].
An in-depth evaluation of RIIIJ was performed against heteromeric channels generated by a
covalent linkage composed of Kv1.2 and all other Kv1s subunits (except for Kv1.8) at different
stoichiometries and arrangements [82]. This work revealed that RIIIJ exquisitely targets asymmetric Kv
channels composed of three Kv1.2 subunits and one Kv1.1 or Kv1.6 subunit. RIIIJ’s apparent affinity
for the asymmetric complex is ~100-fold higher than for the homomeric Kv1.2 complex.
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Recently, the discerning sensitivity of RIIIJ to its heteromeric Kv1 channel target was exploited
to comprehensively classify and characterize individual somatosensory neuronal subclasses within
heterogenous populations of dorsal root ganglion (DRG) neurons [83]. RIIIJ’s selectivity was used to
distinguish two functional Kv1 complexes in mouse dorsal root ganglion (DRG) neurons. One being
RIIIJ’s high-affinity target (3 × Kv1.2 + Kv1.1 or Kv1.6), and the second component characterized by
inhibition at higher RIIIJ concentrations arguably composed of homo-tetrameric Kv1.2 subunits [82].
The functional behavior of large DRG (L-DRG) neurons exposed to RIIIJ was used to classify L-DRGs
in six discrete neuronal subpopulations (L1–L6). Interestingly, this peptide’s block of heteromeric
Kv1 channels in subclass L3 and L5 neurons lead to enhanced calcium signals consistent with
their contribution to repolarization after a depolarizing stimulus, whilst in subclass L1 and L2
neurons, exposure to RIIIJ decreased the threshold for action potential firing. The integration of
constellation pharmacology [66], electrophysiology, and transcriptomic profiling using RIIIJ as a
pharmacological tool served to functionally assess three biological levels spanning the molecular target
Kv1 channel (Kv1.2/Kv1.1 heteromer), the functional characteristics of specific neuronal subclasses and
the physiological system (i.e., proprioception) in which they participate.
Table 1. Some characteristics of known conotoxins targeting the Kv1 channel.
Conopeptide Source Family Target Channel(s) (IC50) References
CPY-Pl1 C. planorbis CPY Kv1.2 (2 µM); Kv1.6 (170 nM) [84]
CPY-Fe1 C. ferruginesus CPY Kv1.2 (30 µM); Kv1.6 (8.8 µM) [84]
κM-RIIIJ C. radiatus M hKv1.2 (33 nM) [80]
κM-RIIIK C. radiatus M hKv1.2 (300 nM)rKv1.2 (335 nM) [79]
Pl14a
(κJ-PlXIVA) C. planorbis J hKv1.6 (1.6 µM) [76]
κ-ViTx C. vigro I2 rKv1.1 (1.6 µM)rKv1.3 [85]
Conkunitzin-S1 C. Striatus Conkunitzins Kv1.7 (< nM) [12]
2.2. Conk-S1
Conk-S1 (Conkunitzin-S1; Figures 2 and 3) was the first reported member of a novel family
of marine toxins characterized by the Kunitz structural fold [52]. Conk-S1 is a 60-residue marine
toxin from the venom of Conus striatus that blocks Shaker [52] and mammalian Kv1 channels [12].
The crystal structure of Conk-S1 displays a Kunitz-type fold in which an NH2- terminal 3-10 helix,
2-stranded β-sheet, and the COOH- terminal α-helix are stabilized by 2 disulfide bridges and a network
of non-covalent interactions [86]. Despite having only two of the three highly conserved cysteine
bridges present in canonical Kunitz peptides, such as bovine pancreatic trypsin inhibitor (BPTI) and
Dendrotoxin-κ, structural analyses using NMR spectroscopy verified the presence of the Kunitz-type
fold not only in Conk-S1 but also in its homolog Conk-S2 [87].
A comprehensive selectivity profile amongst Kv1, Kv2, Kv3, Kv4, BK and EAG channels is
available for Conk-S1 [12]. With such information in hand, it was possible to utilize Conk-S1 as a
pharmacological tool to identify the role of Kv1.7 channels in glucose-stimulated insulin secretion
(GSIS) in pancreatic β cells [12]. Conk-S1 not only was useful as a molecular tool but also was
shown to enhance insulin secretion ex vivo in a glucose-dependent manner in islets of Langerhans as
well as in vivo in anesthetized rats. Rats treated with Conk-S1 did not evidence any adverse effects,
highlighting the potential of Conk-S1 as a therapeutic scaffold for the treatment of hyperglycemia
related disorders.
Mutation of the Shaker K+ channel residue K427 to aspartate enhances Conk-S1 potency of block
>2000-fold, suggesting Conk-S1 interactions with the Kv channel vestibule (see Figure 2b) [52]. Recent
structural, functional, and computational work proposes a novel mechanism of the block for K+ channel
blockers [60]. Conk-S1 does not seem to directly block the ion conduction pathway, but instead, its
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binding causes disruptions in the structural water network responsible for the stabilization of the Kv
channel activated state [88], causing the collapse of the permeation and the consequent hindrance of
K+ ion flow, similar to what has been described to occur during slow inactivation [60]. This systematic
and elegant work was performed on Kv1.2 channels (Conk-S1, IC50: 3.4 ± 1.3 µM) instead of the
previously described highest affinity mammalian target Kv1.7. The affinity of Conk-S1 for human Kv1.7
channels is 37 ± 5 nM (Xenopus oocytes [89]) and 439 ± 82 nM for the mouse orthologue determined in
mammalian cells [12]. Interestingly, comparison of the pore sequences of Kv1.1–Kv1.6 and Shaker
channels lead to the conclusion that Conk-S1’s preferential toxin action against the Drosophila channel
(502 ± 140 nM, Xenopus oocytes) was dominated by aromatic interactions mediated by a phenylalanine
in Shaker position 425, whilst in hKv1.7, a histidine (341) is present in the equivalent position.
The observation that heteromerization with Kv1.7 enhances Conk-S1 affinity towards Kv1.2
containing hetero-multimeric Kv channels [12] suggests that such a mechanism of block would extend
to Kv1.7-mediated current inhibition as well as to other homo and hetero-tetrameric Kv1 channels.
2.3. κ-PVIIA
The venom of Conus purpurascens is a source of the founding member of the kappa conotoxins
κ-PVIIA (or CGX-1051). PVIIA is a 27-amino-acid-long peptide that potently blocks Shaker potassium
channels [72,75]. PVIIA was reported to reduce myocardial lesions in rabbit, rats, and dogs, exhibiting
protective effects relevant to ischemia/reperfusion-induced cardiomyocyte damage [90]. In these
animal models, acute intravenous administration of PVIIA substantially reduces myocardium infarct
size without adverse alterations in cardiovascular hemodynamics [91]. However, attempts to identify
a mammalian target of PVIIA have been unsuccessful with 2 µM PVIIA failing to inhibit Kv1.1 or
Kv1.4-mediated currents expressed in Xenopus laevis oocytes and recorded by two-electrode voltage
clamp [92].
While the mechanism underlying the cardioprotective efficacy of κ-PVIIA is unclear, the reported
preclinical results in animal models of ischemia/reperfusion suggest that κ-PVIIA may represent a
valuable adjunct therapy in the management of acute myocardial infarction [93].
2.4. κ-ViTx
The structural superfamily I2 of Conus peptides was established with the discovery of κ-conotoxin
ViTx in the venom of Conus virgo. In ViTx, four disulfide bridges crosslink a chain of 35 amino acids.
TEVC recordings in Xenopus oocytes showed that ViTx inhibits voltage-gated K+ channels rKv1.1 (IC50:
1.59±0.14 µM) and hKv1.3 (IC50: 2.09±0.11 µM) but not Kv1.2 (up to 4 µM). Activity on other Kv1
channels has not been reported [85].
2.5. SrXIa
SrXIa was purified from the venom of vermivorous Conus spurius and was found to inhibit Kv1.2
and Kv1.6 without apparent effects over Kv1.3 channels. SrXIa does not contain lysine residues and
thus is considered to lack a functional dyad to support Kv1 channel blockade. Moreover, a ring of
arginine including R17 and R29 were shown to be important for its biological activity [94]. Activity on
other Kv1 channels is missing.
2.6. Promiscuous Conotoxins Interacting with Kv1 Channels
2.6.1. pl14a
The J-conotoxin pI14a isolated from the vermivorous cone snail Conus planorbis is 25 amino acids
long, from which six residues form an elongated NH2- terminus and four cysteines are bonded into the
“1-3, 2-4” connectivity, and is decorated with a C-terminal amide group (Figure 3). NMR structure
determination revealed one α-helix and two 3(10)-helices stabilized by two disulfide bridges [76]. pl14a
inhibits Kv1.6 channels (IC50 = 1.59 µM) as well as neuromuscular α1β1εδ and neuronal α3β4 nicotinic
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acetylcholine receptors (IC50s = 0.54 µM and 8.7 µM, respectively). Importantly, 1-5 µM pl14a had
negligible effects over Kv1.1−Kv1.5, Kv2.1, Kv3.4, Nav1.2, or N-type presynaptic Cav channels [76].
An interesting feature of pl14a is that it contains a putative Kv channel blocking “dyad” formed by
residues K18 and T19 as well as a ring of basic residues consisting of R3, R5, R12, and R25. In silico
predictions suggest that pI14a inhibition of Kv1.6-mediated currents is mainly supported by the basic
ring of amino acids [95]; however, this awaits experimental verification.
2.6.2. Tyrosine-Rich Conopeptides CPY-Pl1 and CPY-Fe1
The conopeptide family Y (CPY) was defined by the discovery of two 30-amino-acid-long peptides,
named CPY-Pl1 and CPY-Fe1, found in the venoms of vermivorous marine snails Conus planorbis
and Conus ferrugineus. VDPs belonging to this family do not contain disulfide bridges and appear
unstructured in solution. Nevertheless, the NMR analysis of CPY-PI1 revealed a helical region around
residues 12–18 [84].
Functionally, both peptides are more active against Kv1.6 and Kv1.2 than Kv1.1, Kv1.3, Kv1.4,
and Kv1.5, with CPY-PI1 displaying ~50-fold more potency against Kv1.6 than CPY-Fe1 (IC50 0.17 µM
and 8.8 µM, respectively), being ∼18-fold more potent for pl14a. At 1 µM, these peptides also inhibit
currents mediated by N-methyl-D-Aspartate (NMDA) receptors (NR1–3b/NR2A and NR1–3b/NR2B)
and Nav1.2 channels. Anecdotally, devitellinized oocytes exposed to hydrophobic CPY peptides
become “leaky”, suggesting that these peptides could intercalate into the plasma membrane either to
destabilize it or to perhaps display pore-forming activity [84].
2.6.3. µ-PIIIA
Conotoxin µ-PIIIA and µ-SIIIA inhibit mammalian Nav1.2 and Nav1.7 channels with nanomolar
potency [96] and bacterial sodium channels NaChBac and NavSp1 in the picomolar range [97]. It has
been recently shown that these µ-conopeptides can also selectively inhibit Kv1.1 and Kv1.6 channels
with nanomolar affinity while sparing other Kv1 and Kv2 family members [96]. Functional evaluation
of chimeras between µ-PIIIA sensitive and insensitive isoforms revealed that these toxins interact with
the Kv pore region with subtype specificity largely determined by the extracellular loop connecting the
channel pore and transmembrane helix S5 (turret).
In contrast to all other pore-blocking κ-conotoxins, the binding of µ-PIIIA to Kv1.6 channels
reaches equilibrium after several tens of minutes, pointing towards an alternative Kv1 mechanism of
inhibition for µ-PIIIA. Docking and molecular dynamics simulations were used to assess the interaction
between µ-conotoxins and Kv1 channels [98]. This work proposed similar binding modes of µ-PIIIA to
Kv1.6 and Kv1.1 homomeric channels supported by hydrogen bonding between R and K residues from
µ-PIIIA’s α-helical core and the central pore residues of the Kv channel. In such circumstances, effective
pore blockage would occur by dual interaction of the µ-conotoxin with both inner and outer pore
loops of the Kv channel. This implies that the composition of the channel inner pore loop determines
the orientation of the µ-PIIIA, which is further consolidated by hydrogen bonding with the Kv1
extracellular pore loops. The subtype specificity of µ-PIIIA among the Kv1 family members was then
rationalized by unfavorable electrostatic interactions between charged residues in the pore loops of the
µ-PIIIA-resistant Kv1s.
The apparent binding kinetics of µ-PIIIA to Kv1.6 channels were too slow to allow estimation
of potency from concertation response curves as it is customary for potassium channels blocking
peptides. This poses the question of whether common peptide screenings on Kv channels performed
by relatively short (~5 min) exposures to the toxins are consistently missing positive hits. Alternatively,
binding equilibrium determinations in experiments that extend over tens of minutes may be providing
an overestimation of potency due to intrinsic confounding factors (such as current rundown and cell
viability) inherent to the biological system and experimental conditions used.
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2.6.4. κP-Crassipeptides
From Crassispirine snails, a group of venomous marine gastropods, κP-crassipeptides were
isolated [99]. Three peptides were characterized to be Kv1 channel blockers, CceIXa, CceIXb, and
IqiIXa. The same study showed that, among the tested neuronal hKv1 channels, CceIXb was selective
for Kv1.1 with IC50 ~ 3 µM. In 1 mM concentration, the other two toxins did not elicit any detectable
effects when tested on these Kv1 targets [99]. However, CceIXa and b peptides elicited an excitatory
phenotype in a subset of small-diameter capsaicin-sensitive mouse DRG neurons that were affected
by the Kv1.6 blocker κJ conotoxin pl14a [94,99]. Since κJ conotoxin pl14a is broader in selectivity
among Kv1 channels expressed in DRGs, CceIXa might be more selective for particular combinations
of heteromeric Kv1 channels.
3. Cnidarian Peptides that Inhibit Kv1 Channels
Sea anemones (phylum Cnidarian) produce various classes of peptide toxins targeting a diverse
array of ion channels that serve the functions of defense from predators and immobilization of
potential prey [100]. Some marine toxins found in sea anemones target Kv1 channels in which block
leads to neuronal hyperexcitability and muscle spasms. These marine toxins have been shown to
have important therapeutic applications in the treatment of autoimmune diseases including multiple
sclerosis, rheumatoid arthritis, and diabetes [101,102].
Due to the large diversity of toxins produced from sea anemones and both their functional
convergence and promiscuity, classification of sea anemone toxins has proven difficult. A recent review
has attempted to circumvent this by classifying sea anemone proteinaceous toxins into three major
groups: (1) enzymes, (2) nonenzymatic cytotoxins, or (3) nonenzymatic peptide neurotoxins [103]. The
Kv channel targeting sea anemone toxins all fall into the third group, peptide neurotoxins, which can
be further classified into 9 structural families. To date, of these subfamilies, only six have a Kv-selective
toxin representative (ShK, Kv type 1; Kunitz-Domain, Kv type 2; B-Defensin-like, Kv type 3; Boundless
β-hairpin (BBH), Kv type 4; Inhibitor Cystine-Knot (ICK), Kv type 5; and Proline-hinged asymmetric
β-hairpin (PHAB), Kv type 6; see Table 2).
The anemone VDP toxins interact with Kv1 channels, are typically 17–66 amino acids long, and are
cross-linked by 2–4 disulfide bridges [104,105]. Up to 21 sea anemone toxins are listed as mammalian
Kv1 channel blockers in the kalium database, which populate all Kv types, except Kv type 5. Each of
these types of cnidarian toxins are examined in detail below.
Table 2. Sea anemone peptides directed against Kv1 channel.
Toxin Source Inhibited Kv1 Channels References
Type 1
ShK Stichodactyla helianthus Kv1.1, Kv1.3, Kv1.4, 1.6 [106,107]
AeK Actinia equina
125I α-DTX binding
to synaptosomal membranes (IC50 22 nM)
[108]
AETX K Anemonia erythraea
125I α-dendrotoxinDTX binding
to synaptosomal membranes (IC50 91 nM)
[109]
AsKS Anemonia sulcata Kv1.2 [110,111]
BcsTX1/2 Bunodosoma caissarum
BcsTx1 Kv1.2, Kv1.6
BcsTx2 Kv1.1, Kv1.2, Kv 1.3, Kv1.6, Shaker
IR with nM IC50
BgK Bunodosoma granulifera Kv1.1, Kv1.2, Kv1.3, Kv1.6 [112,113]
HmK Heteractis (Radianthus)magnifica Kv1.2, Kv1.3 [114,115]
Type 2
AsKC1 Anemonia sulcata Kv1.2 [111]
AsKC2 Anemonia sulcata Kv1.2 [116]
AsKC3 Anemonia sulcata Kv1.2 [116]
APEXTx1 Anthopleura elegantissima Kv1.1
SHTXIII Stichodactyla haddoni
125I α-DTXdendrotoxin binding
to synaptosomal membranes (IC50 270 nM)
[117]
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Table 2. Cont.
Toxin Source Inhibited Kv1 Channels References
Type 3
BDS-I Anemonia sulcata Kv1.1–5 < 20% inhibition at 10 µM [116]
APETx1/2/4 Anthopleura elegantissima Kv1.1-6 < 30% inhibition at 100 nM
PhcrTx2 Phymanthus crucifer Slight inhibition on DRG Kv currents at µMconcentrations [118,119]
Type 4
SHTX I/II Stichodactyla haddoni None
Type 5
BcsTx3 Bunodosoma caissarum Kv1.1, Kv1.2, Kv 1.3, Kv1.6, Shaker IR [110]
PhcrTx1 Phymanthus crucifer Slight inhibition on DRG Kv currents at µMconcentrations [120]
Type 6
AbeTx1 Actinia bermudensis Kv1.1, Kv1.2, Kv1.6, Shaker IR [121]
3.1. Kv Type 1 Anemone Toxins
Kv type 1 toxins are toxins that include an ShK motif identified from stichodactylatoxin ShK
extracted from Stichodactyla helianthus. Other VDPs that fall in this family include AeK (Actinia equina),
AETX K (Anemonia erythraea), Kaliseptine AsKS (Anemonia sulcata), BcsTXI/II (Bunodosoma caissarum),
BgK (Bunodosoma granulifera), and HmK (Heteractis magnifica). They are composed of 34–38 amino acids
and cross-linked by three disulfide bridges (3–35, 12–28, and 17–32) [100]; see Figure 4.
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Figure 4. (a) Structures of sea anemone peptide toxins ShK (PDB: 1ROO, [53]), BgK (PDB: 1BGK, [46]),
APETx-1 (PDB: 1WQK, [122]), and BDS-I (PDB: 2BDS, [123]): The location of the disulfide linkages are
shown in green, beta-sheets are in blue, and alpha-helices are in red. (b) Sequence alignment of type 1
sea anemone KV-toxins according to their cysteine framework with the pairings indicated by the lines
linking them: Amino acid identity (dark shade) and similarities (light shade) are shown [110].
3.1.1. ShK
One of the first Kv1 channel blockers characterized was ShK (Stichodactyla helianthus K+ channel
toxin; Figures 2 and 4a [124,125]. ShK potently blocks Kv1.3 and Kv1.1 over Kv1.4 and Kv1.6
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channels [106,107]. The amount of ShK found in the Stichodactyla helianthus body is relatively small,
yet chemical synthesis of the wild-type peptide and its analogs allowed its in-depth study. ShK is a
35-amino-acid peptide with a molecular mass of 4055 Da containing three disulfide-bonded cysteine
pairs (C3–C35, C12–C28, and C17–C32) [53,125]. Surface residues of ShK bind at the entrance of the Kv1
channel and block ion conduction by plugging the pore using Lys22 (Figure 2b). The position of the two
key binding residues (K22 and Y23) in ShK is conserved in related K+ channel blocking peptides from
other sea anemones (Figure 4b) [46]. Alanine scanning experiments also identified three other amino
acids, S20, K22, and Y23, as essential for the binding of ShK to rat brain potassium channels [107]. In T
lymphocytes, Kv1.3 channel activity seems to dominate the membrane potential, where high potency
block of this current by ShK highlights its potential use as an immunosuppressant [106,107,126].
However, this peptide has strong binding affinity for neuronal Kv1.1 as well as for its bona fide
target Kv1.3 in effector-memory T cells [127]. Thus, the identification of ShK analogs that are highly
selective for Kv1.3 over Kv1.1 would enable their use in the treatment of autoimmune diseases such
as rheumatoid arthritis and diabetes [102]. To address this, much effort has been dedicated to the
optimization of ShK’s sequence to bias selectivity towards Kv1.3. For example, the N-terminal extension
on ShK (EWSS) is 158-fold more selective to Kv1.3 over Kv1.1 [127]. Non-peptide-based modifications
of ShK include the addition of a 20 kDa poly(ethylene glycol) in ShK-PEG, which increased ShK
selectivity 1000-fold, reaching picomolar potency in whole-blood T cell assays and improved the
peptide’s half-life in vivo [128].
Albeit with lower potency, ShK also blocks Kv3.2 channel (IC50~0.3 nM, [129]). Hence, the ShK
therapeutic scaffold is being exploited for the development of analogs with improved selectivity
profiles [130]. More selective analogs for Kv1.1 and Kv1.3 were developed by amino acid replacements
with differently charged or non-natural amino acids (ShK-Dap22, IC50 23 pM), analogs containing
phospho-tyrosine (ShK-186, IC50 69 pM), and phosphono-phenylalanine (ShK-192, IC50 140 pM), which
contain non-protein adducts and hydrolysable phosphorylated residues [115,131]. Such work suggests
that selective Kv1.3 antagonists such as ShK-Dap22, for which structural and functional data are
available, might represent promising immunosuppressant leads [106,114].
ShK-K-amide is an ShK analog in which an amidated lysine residue has been added to the
C-terminus, resulting in potent and selective block of Kv1.3 [132]. ShK inhibits Kv1.3 and Kv1.1
channels with similar potencies (IC50 of 9 ± 2 pM and 23 ± 3 pM, respectively). While retaining potency
(IC50 26 ± 3 pM) against Kv1.3 channels, ShK-K-amide’s affinity for Kv1.1 is greatly reduced (IC50
942 ± 120 pM), thus being 36-fold more selective between these two Kv1 isoforms. It is reasoned
that addition of a C-terminal-amidated positive charge by the extra lysine changes the electrostatic
interaction between the peptide’s C and N-termini, resulting in more favorable interaction with Kv1.3
by allowing arginine 1 to engage with the channel vestibule as well as the previously reported strongly
coupled pair R29-S379 in Kv1.3-ShK [127]. However, the extra C-terminal lysine (in ShK-K-amide)
disrupts binding with Kv1.1 by apparently altering K18 and R29 interactions with negatively charged
residues in the channel.
3.1.2. BgK
BgK is a 37-amino-acid peptide isolated from the sea anemone Bunodosoma granulifera, which
blocks Kv1.1, Kv1.2, and Kv1.3 channels [112]. BgK is a 37 amino acid peptide crosslinked by three
disulfide bridges (C2–C37, C11–C30, and C20–C34), and free C-terminal carboxylate. Both natural and
synthetic BgK inhibit binding of 125I-α-DTX to rat brain synaptosomal membranes with nanomolar
potency [112]. Corresponding BgK residues (S23, K25, and Y26) are involved in binding to rat brain
potassium channels Kv1.1, Kv1.2, Kv1.3, and Kv1.6 [133]. BgK does not select between Kv1.1, Kv1.2,
and Kv1.3 channels expressed in Xenopus oocytes, displaying quite similar dissociating constants (Kd
= 6 nM, 15 nM, and 10 nM, respectively [113]). BgK and ShK share 13 residues and present similar but
not exact topologies (Figure 2a) ([46,126] Figure 4b). It has been shown that shortening of K25 side
chain by removal of the four methylene groups dramatically decreases the affinity of BgK towards all
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Kv1 channels [134]. Mutations at position F6 in BgK reduce potency towards both Kv1.2 and Kv1.3
while not affecting Kv1.1, making BgK-F6A selective for Kv1.1 [135]. BgK-F6A increased miniature
excitatory postsynaptic current in neurons while not affecting T-cell activation. This suggests that the
Kv1.1 blockade has potential in neuro-inflammatory diseases including multiple sclerosis and stroke
and BgK-F6A as a scaffold for drug design.
3.1.3. BcsTx1/2
Two toxins from the venom of Bunodosoma caissarum were isolated and named, BcsTX1 and
BcsTx2 [110]. These peptides contained the classical three disulfide bonding pattern of Kv type 1 toxins
and were screened against a panel of Kv channels, displaying no affinity towards channels outside of
the Kv1 subfamily. Both toxins showed differences in their Kv1 selectivity, with BcsTX1 being 10-fold
selective for Kv1.2 (~30 nM) over Kv1.6 (~1.6 µM), which in turn was >10-fold selective over other Kv1
channels examined, while BcsTX1 was less selective, displaying the highest affinity for Kv1.6 but less
than 10-fold greater than Kv1.1, Kv1.2, and Kv1.3 [110].
3.1.4. Other Kv Type 1 Toxins
Other Kv type 1 sea anemone toxins are known to interact with Kv1 channels; however, little
follow has been completed looking at their selectivity or therapeutic potential in depth. The sea
anemone Heteractis magnifica venom contains the VDP, HmK. It is 35 amino acids long, having an
identical molecular weight (MW 4055) to ShK, with 60% homology. HmK is approximately 40%
identical to BgK and AsKS (Figure 4b). Partial reduction at acidic pH and rapid alkylation allowed
the full assignment of the disulfide linkages (C3–C35, C12–C28, and C17–C32). HmK inhibits the
binding of 125I-α-DTX to rat brain synaptosomal membranes with a ~1 nM Ki and block Kv1.2 channels
and facilitates neuromuscular junction acetylcholine [114]. Alanine scanning analyses proved that six
amino acids (D5, S20, and the dipeptides KY22–23 and KT30–31) are crucial for binding to rat brain Kv
channels and perfectly conserved between BgK, ShK AsKS, and HmK [114].
AeK, isolated from Actinia equine, is a Kv1 channel toxin that inhibits the binding of 125I-α-DTX
rat synaptosomal membranes in a dose-dependent manner with an IC50 of 22 nM [108]. The complete
amino acid sequence of AeK is composed of 36 amino acid and six cysteine residues. AeK’s three
disulfides are located between C2–C36, C11–C29, and C20–C33. AeK contains the canonical dyad for
Kv channel block formed by K22 and Y23. AeK is similar to AsKS structurally with which it shares
86% sequence homology, 53% with BgK, and 36% with ShK (Figure 4b). However, the selectivity of
this peptide has not been addressed functionally.
AsKS, or kaliseptine, is a 36-amino-acid peptide isolated from the sea anemone Anemonia sulcata that
blocks Kv1 channels and impedes the binding of 125I-α-DTX to receptors in rat brain membrane [111].
AsKS shares 49% sequence homology with BgK toxin ([134] Figure 4b) but differs in two of its cysteine
residues (C33 and C36) and the C-terminus. Dendrotoxin I (DTX-I) is a potent blocker of Kv1.1-,
Kv1.2-, and Kv1.6-mediated currents in Xenopus oocytes. Despite being structurally dissimilar, AsKS
appears to share a receptor site in Kv1 channels with the kalicludines (AsKC) and DTX-I. The simple
comparison on the capacity of AsKS inhibition for Kv1.2 channel with inhibition 125I-α-dendrotoxin
binding to neuronal membranes should be followed with a more in-depth investigation.
The mature AETxK peptide from Anemonia erythraea is 34 residues long; six cysteines are paired
to form three disulfide bridges (C2–C34, C11–C27, and C16–C31) and presents a canonical Kv
channel-blocking dyad comprised of K21 and Y22. AETxK is 59% and 65% homologous to ShK and
HmK respectively, whereas it shares 41–44% sequence homology to all other type 1 anemone toxins
(Figure 4b). AETxK blocks 125I-α-DTX binding to rat synaptosomal membranes with an estimated IC50
of 91 nM [109]. No electrophysiological or related functional data has been reported for this peptide;
therefore, its selectivity is unknown [109].
These VDP are all similar to the well-studied ShK; thus, in-depth selectivity profiling is required
for these toxins on both homomeric and heteromeric Kv1 channels. These toxins have the potential
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as scaffolds for therapeutics targeting of autoimmune disorders, stroke, diabetes, multiple sclerosis,
and others. None of these toxins have been tested on hetero-tetrameric Kv1 channels and, with their
divergent affinities across the Kv1s, may provide interesting routes to discovering selective compounds
for various heteromeric Kv1 channels.
3.2. Kv Type 2 Anemone Toxins
Kv type 2 anemone toxins all contain a kunitz-type motif and function as both protease inhibitors
and Kv channel blockers. They were first isolated from sea anemones Anemonia sulcata and named
kalicludines (AsKC1–AsKC3) [130]. However, other Kv type 2 inhibitors have been discovered including
APEKTx1 (Anthopleura elegantissima) [136] and SHTXIII (Stichodactyla haddoni) [117]. When compared
to Kv type 1, Kv type 2 anemone toxins typically have lower affinity towards Kv1 channels, making
their biological role unclear. They may act to paralyze prey through their dual action protease/Kv
channel activity, to provide protection for prey/predator proteases (or, in a similar fashion, to provide
protection for their own venom components when injected into their prey/predator), or to act to
regulate digestive mechanisms [137]. AsKC1-3 (kalicludines 1–3), are composed of 57–60 amino acid
residues with protease inhibitor activity [111]. A mutation at position 19 lowers their inhibitory effect
that linked to the sequence homology of BPTI, protein Kunitz-type protease inhibitors [104]. AsKC1
and AsKC2 contain the fully conserved dyad K5/L9 responsible for competing with the DTX-I site in
Kv1 channels. They share ~40% amino acid homology with other toxins from venomous animals, such
as DTX and BPTI, but AsKC1 and AsKC2 have different specificity from AsKC3 [111,130]. However,
further studies should be conducted on the selectivity of these toxins.
In contrast, APEKTx1 has an in-depth study into its selectivity across a variety of ion channels.
This study revealed potent activity against Kv1.1 (0.9 nM) with >1000-fold selectivity over other Kv1
channel members, making it an excellent probe into Kv1 channelopathies.
3.3. Kv Type 3 Anemone Toxins
Kv type 3 anemone toxins contain a β-defensin-fold characterized by a short helix or turn followed
by a small twisted antiparallel β-sheet. β-defensin are antimicrobial peptides, and anemones have
weaponized them as neurotoxins [138] to target not just Kv channels but also Nav and acid sensing ion
channels (ASIC) [139,140]. Five Kv type three toxins are shown to have affinity towards Kv1s although
very modestly. These include BDS-I (blood depressing substance I from Anemonia sulcata), APETx1/2/4
(Anthopleura elegantissima), and PhcrTx2 (Phymanthus crucifer). BDS-I was first characterized as an
antihypertensive and antiviral compound [141]. It was later shown that BDS-I inhibited Kv3.1, Kv3.2,
and Kv3.4 with nanomolar concentrations, with only a week inhibitory effect of Kv1.1–5 [116]. BDS-1
has also been shown to inhibit voltage-gated sodium channels in the nanomolar range [142]. Similar to
BDS-I, APETx1, 2, and 4 have similar issues with selectivity towards Kv1s. APETx1 and APETx4 are
more selective for hERG [118,143], while APETx2 is selective for ASIC channels [138]. PhcrTx2 showed
little inhibition of the total DRG Kv channels currents (IC50 6.4 µM) or heterologously expressed Kv1
channels [119]. Currently, no Kv type 3 anemone toxin is specific for Kv1s, suggesting this family of
toxins may not be Kv1 therapeutics of potential pharmacological agents. However, future studies will
be interesting to address if the Kv type 5 anemone toxins are all antimicrobial and, if so, do they target
prokaryotic potassium channels.
3.4. Kv Type 4 Anemone Toxins
Kv type 4 anemone toxins are characterized by a novel fold called boundless β-hairpin. SHTX I
(28 residues) and SHTX II (an analog of SHTX I, 28 residues), based on their structure, has been shown
that SHTX I and II have only been shown to inhibit binding of 125I-DTX [117] with no channel blocking
specificity described. Further studies are required to ascertain selectivity and potency towards Kv1s to
assess their future potential as therapeutics or pharmacological tools
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3.5. Kv Type 5 Anemone Toxins
Kv type 5 anemone toxins contain the ubiquitous, inhibitor cysteine knot (ICK) motif. BcsTx3
is a 50-amino-acid peptide and Kv toxin extracted from the venom of the sea anemone Bunodosoma
caissarum with a molecular weight of 5710.52 Da and four disulfide bridges. High identity (65.3% and
63.3%) with BscTx3 and identical positions of cysteine residues have been found in toxins isolated from
Nematostella vectensis and Metridium senile. Another Kv type 5 anemone toxin, PhcrTx1 (Phymanthus
crucifer), has low affinity modulatory actions on Kv1 channels; however, its main target has been shown
to be ASIC channels [120].
Activity investigation of BcsTx3 has been done by Reference [110] on 12 cloned voltage-gated
potassium channels and 3 voltage-gated sodium channels. It was shown that BcsTx3 blocks Kv channels
Kv1.1, Kv1.2, Kv1.3, Kv1.6, and Shaker IR (inactivation removed) and did not show any activity on
sodium channels. The blockage activity of BcsTx3 is not voltage dependent, and the binding site is
located at the extracellular side. The lysine and tyrosine functional dyads are absent although present
in most of the pore blocker toxins. BcsTx3 binds to Shaker IR through multipoint interaction due to
existence of two putative dyads (R5-Y6 and R39-Y40). The evolution of the neurotoxin gene family has
been followed by sequencing of the entire genome of N. vectensis. It has been shown that peptides
in sea anemones responsible for blocking Kv channels evolved at least five times independently but
that adaptive evolution took place in a common ancestor [144]. It remains to be seen if any Kv type 5
anemone toxins will provide selectivity within the Kv1 channel family, and thus, any potential as a
therapeutic scaffold so far is limited. However, the ICK motif is highly stable, resistant to denaturation
and proteolysis [145], which make excellent potential therapeutics if selectivity can be conferred.
3.6. Kv Type 6 Anemone Toxins
Kv type 6 anemone toxins are the shortest of Kv-type sea anemone toxins and contain a
proline-hinged asymmetric β-hairpin fold. AbeTx1 is a toxin with a unique primary structure
isolated from nematocysts of the sea anemone Actinia bermudensis. It is short flexible random-coil-like
conformational peptide chain of 17 amino acids with a tendency to form β-sheet (aromatic or aliphatic
amino acids are not present, but it contains a high proportion of Lys and Arg, and two disulfide bridges
between C1–C4 and C2–C3) [121].
The activity of AbeTx1 was tested on 12 subtypes of Kv channels (Kv1.1–Kv1.6; Kv2.1; Kv3.1;
Kv4.2; Kv4.3; Kv11.1; and Shaker IR) and three voltage-gated sodium channels (NaV1.2, NaV1.4, and
BgNaV). It has been shown that AbeTx1 is selective for Shaker-related K+ channels and is capable
of inhibiting K+ currents by blocking the K+ current of Kv1.2 or by altering activation of Kv1.1 and
Kv1.6 channels. AbeTx1 showed no activity on sodium channels, but the same concentration (3 µM)
inhibits the current of Kv1.1, Kv1.2, Kv1.3, Kv1.6, and Shaker IR channels [121]. It is known that the
mechanism of Kv channel toxins is multipoint interaction binding to ring based amino acid, and due
to the presence of six such amino acid rings (R1, R9, R11, K3, K7, and K13), AbeTx1 toxins interact
with Kv1.1 and Kv1.6 channels. Electrophysiological experiments were performed to determine the
mechanism of action, and it has been discovered that probably AbeTx1 toxin binds on the outer side of
Kv1.2 and Kv1.6 channels since its effect is reversible (current was recovered). Competitive binding
experiments with TEA showed that binding sites for both ligands are not overlapping completely on
Kv1.1, which is not the case with Kv1.6 channels due to less voltage dependence of blockage of Kv1.1
with membrane depolarization [121].
Also, alanine point-mutated analogs were tested on Kv1.1 and Kv1.6 channels. Six synthetic
analogs were used to test a multipoint interaction of the toxin to the channel’s binding site, and it has
been shown that loss of the side chains will lead to decreasing activity of analogs [121].
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4. Non-Peptidyl Kv1 Channel Inhibitors
4.1. Gambierol
One of the non-peptidyl toxins from the ciguatera group (CigTXs) is gambierol (Figure 5), marine
polycyclic ether toxin isolated from marine dinoflagellate Gambierdiscus toxicus showing acute toxicity
in mice (LD50 = 50 mg/Kg, ip; [146]). These CigTXs are accumulated throughout the marine food chain,
causing hypotension, bradycardia, respiratory difficulties, and paralysis [147]. Although CigTXs are
toxic for Nav channels, gambierol inhibits only Kv1 potassium channels [147,148].
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Gambierol is lipophilic and can pass through the cell membrane. This was confirmed as Gambierol
inhibited closed channels no matter which side the toxin was applied [148]. Gambierol has heptacyclic
and tetracyclic analogs that are specific inhibitors for the Kv1.2 channel expressed in CHO cells with
IC50s of 0.75, 7.6, and 28 nM, respectively [146]. However, the dose-dependent leak current induced
by these compounds might be behind their cytotoxic effect. Screening of Gambierol against other Kv
channels revealed that Kv2 and Kv4 were insensitive to 1 µM gambierol but fully repressed Kv3.1
channels [149]. The same study showed ~70% inhibition of K+-mediated currents by Kv1.4 using
100 nM Gambierol.
According to Kopljar, et al., 2009 [149], Kv3 channels inhibition occurs when channels are
deactivated, suggesting a mechanism related to gating modification. Swapping of the S5–S6 linker
between Kv3.1 and Kv2.1 channels gave no differences in selectivity of gambierol to either of the
channels, indicating that gambierol is not an external pore blocker. Kv1 and Kv3 channels contain
threonine residues in the inner permeation pathway, while the insensitive Kv2 and Kv4 channels
have valine at the same position. After the replacement of threonine with different moieties, it was
confirmed that hydrogen bonding capable amino acids (serine and lysine) contribute to the high affinity
of gambierol to Kv3.1 channels. The T427 residue between the S5 and S6 segments of Kv3.1 channels
interacts with one of the ether oxygens of the toxin, thereby inhibiting permeation of K+ ions and
stabilizing the closed state.
4.2. Aplysiatoxin Derivatives
Marine cyanobacteria are a source of many toxins, including a recently discovered group of
Kv1.5 blockers called Aplysiatoxins (ATXs). ATXs and related analogs, namely Oscillatoxins and
nhatrangins (Figure 6), are 27 bioactive dermatoxins polyketide compounds that were isolated from
several marine cyanobacteria species with antiproliferative activity, tumor-promoting properties,
proinflammatory actions, and antiviral activity (see Reference [150]). According to the structural
characteristics, ATXs were divided into three categories: (1) the ABC tricyclic ring systems with carbon
numbers of 6/12/6, 6/10/6, and 6/6/6 (e.g., Debromoaplysiatoxins and neo-debromoaplysiatoxins) [151];
(2) the AB spirobicyclic ring system (e.g., Oscillatoxin D) [152], and (3) acyclic structures such as
Nhatrangins [153].
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In addition to their various structures, ATX derivatives exhibit selectivity and potency against
Kv1.5 channels, a possible pivotal target for new treatment of atrial tachyarrhymias with minimal
potential for deleterious side effect [151,154,155]. Although further studies are still ongoing to establish
the Kv1.5 inhibition mechanism by these various bioactive compounds, researchers suggested two
mechanisms. One is the direct ion channel modulation by direct blocking of the pore. The other
proposed mechanism is the indirect modulation of the Kv channel by activating protein kinase C [154].
5. Kv1-Active Toxins in Research and Drug Discovery
Venom-derived toxins have been paramount in the identification and study of ion channels.
Neuronal Kv1 heteromeric complexes were first recognized thanks to snake dendrotoxins and were
identified by isoform-specific antibody fractionation [36,37,40]. We have learned that the majority
of Kv1 channel complexes present in the nervous system are hetero-tetrameric combinations of Kv1
α-subunits, while only a small fraction of channels are homo-tetramers (e.g., neuronal: Kv1.2 and
1.4; immune system Kv1.3). The composition, stoichiometries, and subunit arrangements of Kv1
complexes expressed in different tissues and cells remains to be fully identified. As seen in the sections
above, many of the venom-derived toxins published have not been screened against homomeric Kv1
channels and thus lack information of biological potential. To understand the therapeutic potential
of these toxins, it is necessary to study their effects on relevant heteromeric Kv channel complexes.
This requires efforts that include but are not limited to the generation and functional characterization
of concatenated (or tandem) hetero-tetramers [156,157], as proxies of the physiological targets, in
bioactive-driven molecular tool development and drug discovery.
By examining venom-derived peptides on hetero-tetrameric Kv1, it has recently been discovered
that some VDP display significantly higher potencies for heteromeric Kv1s than those with the
same contributing homomeric channel isoforms. For example, testing of conotoxin κM-RIIIJ over 12
different heterodimers containing Kv1.2 subunits, Cordeiro et al. showed that RIIIJ was most potent
against Kv1.1/Kv1.2 heterodimers without apparent regard for their arrangement, showing significant
discrimination against other heterodimeric constructs including those formed by association of Kv1.2
with Kv1.5 or Kv1.6. Further functional analyses showed that RIIIJ was indeed ~100 more potent
against hetero-tetramers made of three copies of Kv1.2 α-subunits and one of either Kv1.1 or Kv1.6 in a
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3:1 stoichiometry [82]. This detailed functional and biochemical characterization then enabled the use
of RIIIJ as a molecular tool for the classification of live large DRG neurons into six discrete functional
populations [83]. An approach that can be exploited to accelerate the classification and study of other
cell types within mixed population.
The thorough functional characterization of Conkunitzin-S1 allowed the identification of Kv1.7
channels in pancreatic beta cells as contributors in glucose-stimulated insulin secretion [12]. As shown
for the RIIIJ/Kv1.2 interactions, the presence of the Kv1.7 α-subunit confers sensitivity to Conk-S1 to a
Kv1 hetero-tetramer. In contrast to RIIIJ, Conk-S1 (and Conk-S2) appears to be able to discriminate
different Kv1 targets based on their relative positioning [12]. Thus, hinting to the Conks’ potential as
molecular tools in the study of heteromeric Kv1 channels in native tissues.
The thorough characterization and in vivo study of Conk-S1 was possible due to the production
of high yields by recombinant expression of the peptide in E. coli [52], which guarantees inexpensive
production. Much like monomeric insulin, Conk-S1 is a small peptide (<10 kDa) in which therapeutic
potential for the treatment of hyperglycemic disorders is supported principally by its effectiveness,
in vivo and ex vivo, to enhance insulin secretion and lower glucose levels in a strictly glucose
dependent manner because the targeted Kv1.7 channel opens at depolarized potentials that are
achieved upon increases in blood glucose (i.e., postprandial). Consequently, Conk-S1 treatment
appears to modulate pancreatic β-beta cell excitability only at stimulatory glucose concentrations
where bursting electrical activity is observed but not at low/basal glucose concentrations, eliminating
the risk of hypoglycemia [12]. This is advantageous because the current drugs used to ameliorate
diabetes are effective at lowering blood glucose but do so regardless of the basal conditions. Hence,
acute, delayed, and persistent hypoglycemia constitutes the most frequent adverse effect associated
with sulfonylureas (KATP channel inhibitors) and insulin-based therapies, obliging frequent monitoring
of blood glucose concentrations [158]. Furthermore, intraperitoneal Conk-S1 injections neither affected
basal glucose levels nor produced adverse cardiovascular or neurological side effects in vivo [12],
highlighting the safety of targeting Kv1.7 channels. Nevertheless, the identification and validation of
biological target(s) as well as prediction of biological activities of Conk-S1 must be verified in alternative
systems including animal models in order to ascertain the mechanism of action behind Conk-S1’s
pro-insulinogenic effects. Further, Structure-Activity Relationship (SAR)-aided computational work
would be useful to aid functional refinements in the selectivity and potency of Conk-S1 for its
development as a therapeutic to minimize potential side effects and to decrease production costs.
Much has been done in the case of the anemone toxins. For instance, ShK is considered the most
potent blocker for Kv1.3 channels with an IC50 of 10 pM [106]. However, it also potently blocks Kv1.1,
1.4, and 1.6 channels [131,159]. Kv1.3 has been shown to be a potential target of immune-modulators;
hence, in order to enhance its selectivity over other targeted Kv1 isoforms, analogs of ShK have been
generated [115]. These efforts paved the way for the development of a leading blocker called ShK-186,
which has a 100-fold improvement in selectivity for Kv1.3 over Kv1.1, 1.4, and 1.6 channels [160].
Currently known as dalazatide, it successfully passed phase 1 clinical trials in 2016 and entered phase 2
in 2018 for the treatment of several autoimmune diseases like inclusion body myositis, lupus, multiple
sclerosis, psoriasis, rheumatoid arthritis, type 1 diabetes, and inflammatory bowel diseases. Promising
newer generation, ShK analogues are currently under development [102].
6. Challenges and Outlook
In this review, a conscious attempt was made to provide an overview of those Kv1-targeted
marine bioactives for which functional data including potency and selectivity has been reported.
The availability of such information has allowed their development as molecular tools, as are the cases
of κ-RIIIJ and Conk-S1, and therapeutically promising pharmacological scaffolds like ShK or Conk-S1.
The wealth of marine bioactive molecules targeting Kv1 channels is immense, yet the vast majority
has been characterized only at the sequence level. The collection of marine toxins presented here was
focused around Kv1 channel modulatory activity. However, the selectivity profiles of most marine
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toxins, both the peptides and non-peptides, are absent or inadequate; hence, further work is necessary
to assess their real potential as research tools and therapeutics.
Competition binding data is customarily reported for venom-derived compounds, but this is
at best indicative of their potential bioactivity. Comprehensive functional profiling is fundamental
to attest to the potential of the abundance of toxins identified, albeit it is not achieved without
substantial challenges. First, the primary sequence of venom derived peptides is used to predict
their 3D structure and to guide inference of potential targets. Unfortunately, similar scaffolds are
often used to target across families of ion channels and enzymes; therefore, functional verification is
an absolute requirement. Second, most selectivity screens to determine specificity of Kv1-targeted
compounds are limited to their functional assessment in homo-tetrameric Kv1 channels assembled
upon expression of a single α-subunit in heterologous systems. Most native Kv channels are not
homomeric but heteromeric complexes formed by up to four different α-subunits, as is the case of
the CNS and PNS Kv channels, and thus, natural bioactive species such as marine toxins and VDPs
have evolved to target heteromeric combinations. These natural molecules have been selected through
evolution to serve as molecular tools for the study of native Kv channels. Furthermore, the study of
the molecular determinants guiding marine bioactive targeting of heteromeric Kv channels would aid
the design of pharmacological agents for the treatment of various channelopathies.
κ-conotoxins, such as RIIIK, RIIIJ, Conk-S1, and Conk-S2 toxins, have been shown to discriminate
among targets based on heteromeric composition and order of connectivity [12]. Naturally evolved K+
channel-targeted ligands may become instrumental in the study of heteromeric Kv1 channels in live
biological systems allowing facile determination of composition and physiological function. Efforts
must be made towards bioactivity determination in hetero-multimeric Kv1 channels in heterologous
systems and by coupling functional studies with single cell transcriptomics/proteomics of primary
cultures. The findings from such work would provide invaluable to the development of leading drugs
against heteromeric channels associated with Kv1 channelopathies [25].
VDP inhibitors select among heteromeric Kv1 channel targets according to their α-subunit
identities, their stoichiometry, and their arrangement by binding across monomeric boundaries.
This could account for the diversity of selectivity “fingerprints” observed in native cells/tissues and
highlights marine toxin relevance as molecular tools and pharmacological applications. The potency
and selectivity of bioactives found in nature provides a wealth of scaffolds with therapeutic potential.
From one side, the molecular understanding of the ion channel pore structure was revealed by using
natural peptide-based toxins as molecular probes. On the other hand, better understanding of the Kv1
channels as drug targets for the treatment of disease is crucial for developing promising therapies.
Comparatively speaking, few marine toxins have been functionally explored in enough depth to
be considered for research or clinical purposes. Only a few labs in the world have full capabilities
to perform all: discovery, synthesis/production, functional characterization, and experimentation in
animal models. Therefore, collaboration between expert labs from each and all disciplines involved is
an absolute requirement for the advance of the field.
Despite the high interest in the discovery of novel marine toxins, many challenges exist in
advancing them into therapeutically active compounds. Amongst those challenges, the development
of adequate transferable human assays to assess compound’s selectivity and off-target activity is
paramount. Selectivity and SAR screens are time and labor intensive, requiring large amounts of
pure material. For example, synthesis and purification of biologically active peptides are ridden
with numerous potential pitfalls such as the selection of the optimal prokaryotic or eukaryotic
expression host (bacteria, yeast, or mammalian cell lines). The production of recombinant proteins has
predominantly used bacterial expression due the ability to generate high protein yields from large
volume cultures of fast-growing, low-cost bacteria [161,162]. However, when the protein products
involve eukaryotic posttranslational modifications, mammalian or insect cells become the system of
choice. Often, functionally, many marine peptides require proper folding supported by their cysteine
connectivity, which can curtail yields of active proteins [163] and/or incorporate posttranslational
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modifications critical for their activity. Despite the advantages of eukaryotic expression systems,
higher production costs preclude their use [164]. Recently, periplasmic peptide expression in E. coli
has made use of the oxidizing environment to produce folded peptides (i.e., Reference [165]). While
this has the potential to speed up protein production, it is limited as targeting across the cytoplasmic
membrane can substantially limit periplasmic yields [166,167]. Marine non-peptidyl compounds also
pose challenges inherent to their chemistry and organisms that produce them [168]. However, once
production of marine compounds is achieved, their stability, formulation, delivery, and antigenicity
need to be overcome. Despite these limitations, the potential therapeutic abilities of marine natural
products are unquestionable. Successful examples include Zinconotide (Prialt, sever chronic pain),
Cytarabine (Cytosar-U, chemotherapy medication), Vidarabine (Vira-A, antiviral drug), Brentuximab
Vedotin (Adcetris, chemotherapy medication), Eribulin Mesylate (Halaven, chemotherapy medication),
Omega-3-acid ethyl esters (Lovaza, diet and exercise drug which reduces triglycerides), Trabectedin
(Yondelis, chemotherapy medication), Fludarabine Phosphate (Fludara, chemotherapy medication),
Nelarabine (Arranon, chemotherapy medication), and Iota-carrageenan (carragelose, Antiviral drug),
with ~30 in various clinical phase I-IV trials (for a recent review, see Reference [169]).
Marine toxins remain a relatively under-explored source of bioactives targeting Kv1 channels.
Technological advances in transcriptomics and proteogenomic will enable the expedited identification
of novel marine toxin repertoires, will explore the diversity of their function based on known peptide
scaffold, and will understand the relationships of structure-function aspects of these toxins with much
more still that remains to be discovered. Importantly, bioactive function can only be determined
experimentally. The use of marine toxins and novel, integrative strategies provide powerful approaches
to functionally define specific cellular types underlying physiology in health and diseased states.
Given the laborious nature of electrophysiological recordings, high-throughput functional assessment
platforms involving automated patch clamp are fundamental for substantial output increase in the
discovery of novel ion-channel targeting molecules and the advancement of the venom-derived drug
discovery field.
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